Chiun-Sheng Huang

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes Fr...

JAMA oncology · 1 november 2025

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonstero...

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 mei 2025

Imlunestrant with or without Abemaciclib in Gevorderd Breast Cancer.

The New England journal of medicine · 27 maart 2025

Overleving met trastuzumab-emtansine bij residueel HER2-positief mammacarcinoom: KATHERINE definitieve OS

The New England journal of medicine · 16 januari 2025

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Tri...

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 november 2024

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the A...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024-11

Ribociclib plus endocriene therapie bij vroeg mammacarcinoom: NATALEE fase III

The New England journal of medicine · 21 maart 2024

T-DXd versus T-DM1 bij HER2-positief mammacarcinoom: DESTINY-Breast03 OS

Lancet (London, England) · 14 januari 2023

Abemaciclib plus endocriene therapie bij hoogrisico mammacarcinoom: monarchE vierjaars

The Lancet. Oncology · 2023-01

Palbociclib plus letrozol bij Aziatische postmenopauzale vrouwen met HR-positief mammacarcinoom

European journal of cancer (Oxford, England : 1990) · 2022-11

Trastuzumab deruxtecan versus T-DM1 bij HER2-positief mammacarcinoom: DESTINY-Breast03 fase III

The New England journal of medicine · 24 maart 2022

T-DM1 plus pertuzumab versus taxaan-trastuzumab-pertuzumab na anthracycline bij HER2-positief mammacarcinoom: KAITLIN fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 februari 2022

Celcyclusremming en immuunrespons met abemaciclib-anastrozol bij mammacarcinoom

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 februari 2020

Neoadjuvant T-DM1 plus pertuzumab bij HER2-positief mammacarcinoom: KRISTINE update

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 september 2019

T-DM1 bij residueel invasief HER2-positief mammacarcinoom na neoadjuvant: KATHERINE fase III

The New England journal of medicine · 14 februari 2019

Neoadjuvant trastuzumab-pertuzumab-chemotherapie versus T-DM1-pertuzumab bij HER2-positief mammacarcinoom: KRISTINE

The Lancet. Oncology · 2018-01

Chirurgische ovariëctomie in luteale versus folliculaire fase plus tamoxifen bij premenopauzaal gemetastaseerd mammacarcinoom

European journal of cancer (Oxford, England : 1990) · 2016-06

Adjuvant lapatinib en trastuzumab bij vroegstadium HER2-positief mammacarcinoom: ALTTO

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 april 2016

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine bij HER2-overexpresserend gemetastaseerd mammacarcinoom

The Lancet. Oncology · 2016-03